Search

Alfred W Sandrock

Deceased

from Newbury Park, CA

Get Report
Also known as:
  • Brenda Stansbury
Phone and address:
541 Strauss Dr, Thousand Oaks, CA 91320
(805)4994601
Related to:
Connected to:

Alfred Sandrock Phones & Addresses

  • 541 Strauss Dr, Newbury Park, CA 91320 • (805)4994601
  • Thousand Oaks, CA
  • Boston, MA
  • Brookline, MA
  • Newton, MA
  • 2412 Cesar E Chavez Dr, Santa Maria, CA 93458
  • Milton, MA
  • N Falmouth, MA
  • Mountain View, CA
  • Torrance, CA
  • N Falmouth, MA
  • Springfield, MA

Work

  • Company:
    Massachusetts General Hospital
  • Address:
    55 Fruit Street, Boston, MA 02114

Education

  • School / High School:
    Harvard Medical School
    1988

Skills

Pharmaceutical Industry • Clinical Development • Biopharmaceuticals • Lifesciences • Drug Development • Biotechnology

Languages

English • Japanese

Awards

Healthgrades Honor Roll

Ranks

  • Certificate:
    Neurology, 1994

Industries

Biotechnology

Specialities

Neuropsychiatry (Neurology)

Resumes

Alfred Sandrock Photo 1

Chief Medical Officer

view source
Position:
SVP, Development Sciences at Biogen Idec
Location:
Greater Boston Area
Industry:
Biotechnology
Work:
Biogen Idec - Cambridge, MA, USA since Mar 2011
SVP, Development Sciences
Biogen Idec, Inc. 2006 - 2011
SVP, Neurology R&D
Education:
Harvard Medical School 1979 - 1988
MD Harvard University 1981 - 1986
PhD, Neurobiology Stanford University 1975 - 1979
BA, Human Biology
Skills:
Pharmaceutical Industry
Clinical Development
Biopharmaceuticals
Lifesciences
Drug Development
Biotechnology

Us Patents

  • Treatment For Multiple Sclerosis

    view source
  • US Patent:
    20090202527, Aug 13, 2009
  • Filed:
    Nov 18, 2005
  • Appl. No.:
    11/719660
  • Inventors:
    Michael Panzara - Winchester MA, US
    Alfred Sandrock - Newton MA, US
  • Assignee:
    BIOGEN IDEC MA INC. - Cambridge MA
  • International Classification:
    A61K 39/395
    A61K 38/02
  • US Classification:
    4241331, 514 2, 4241721
  • Abstract:
    Methods of treating multiple sclerosis and other disorders are disclosed.

  • Therapies For Chronic Inflammatory Demyelinating Polyneuropathy Using Interferon-Beta

    view source
  • US Patent:
    20120058083, Mar 8, 2012
  • Filed:
    Nov 11, 2010
  • Appl. No.:
    12/944396
  • Inventors:
    Alfred Sandrock - Newton MA, US
  • Assignee:
    Biogen Idec MA Inc. - Weston MA
  • International Classification:
    A61K 38/21
    A61P 25/02
    C07K 14/565
  • US Classification:
    424 856, 530351
  • Abstract:
    The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, chronic demyelinating neuropathies, e.g., CIDP. The methods involve the administration of IFN-β therapeutics.

  • Therapies For Chronic Inflammatory Demyelinating Polyneuropathy Using Interferon-Ss

    view source
  • US Patent:
    20060182715, Aug 17, 2006
  • Filed:
    Sep 26, 2003
  • Appl. No.:
    10/529522
  • Inventors:
    Alfred Sandrock - Newton MA, US
  • International Classification:
    A61K 38/21
    A61K 39/395
  • US Classification:
    424085600, 424178100
  • Abstract:
    The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, chronic demyelinating neuropathies, e.g., CIDP. The methods involve the administration of IFN-β therapeutics.

  • Methods Of Treating Multiple Sclerosis And Preserving And/Or Increasing Myelin Content

    view source
  • US Patent:
    20140163100, Jun 12, 2014
  • Filed:
    May 25, 2012
  • Appl. No.:
    14/119373
  • Inventors:
    - Cambridge MA, US
    Gilmore O'Neill - Medford MA, US
    Alfred Sandrock - Newton MA, US
  • Assignee:
    Biogen IDEC MA Inc. - Cambridge MA
  • International Classification:
    A61K 31/225
  • US Classification:
    514547
  • Abstract:
    Methods of treating multiple sclerosis in a subject, including: reducing the frequency of relapse, reducing the annualized relapse rate, reducing the risk of disability progression, reducing the number of new or newly enlarging T2 lesions, reducing the number of gadolinium lesions; and methods of preserving/increasing myelin content in a subject having multiple sclerosis; by daily administering a composition containing a fumarate, such as dimethyl fumarate or monomethyl fumarate, to the subject.

Medicine Doctors

Alfred Sandrock Photo 2

Dr. Alfred W Sandrock, Boston MA - MD (Doctor of Medicine)

view source
Specialties:
Neuropsychiatry (Neurology)
Address:
15 Parkman St, Boston, MA 02114
(617)7243914 (Phone), (617)7266991 (Fax)
Certifications:
Neurology, 1994
Awards:
Healthgrades Honor Roll
Languages:
English
Japanese
Hospitals:
15 Parkman St, Boston, MA 02114

Massachusetts General Hospital
55 Fruit Street, Boston, MA 02114
Education:
Medical School
Harvard Medical School
Graduated: 1988
Medical School
Massachusetts General Hospital
Graduated: 1988
Medical School
Mass Gen Hosp
Graduated: 1988
Alfred Sandrock Photo 3

Alfred William Sandrock, Boston MA

view source
Specialties:
Neurology
Psychiatry
Work:
Wac 835 Neurology Associates
15 Parkman St, Boston, MA 02114
Education:
Harvard University(1988)
Name / Title
Company / Classification
Phones & Addresses
Alfred Sandrock
Executive
Biogen
Biotechnology
225 Binney St, Cambridge, MA 02142
241 Binney St, Cambridge, MA 02142
250 Binney St, Cambridge, MA 02142

Youtube

Alfred Sandrock, MD, PhD: Progressing Parkins...

Alfred Sandrock, MD, PhD: Progressing Parkinson's ...

The executive vice president and chief medical officer of Biogen expla...

  • Duration:
    3m 7s

2017 WNIF | 1:1 Fireside - Alfred Sandrock

2017 WNIF | 1:1 Fireside - Alfred Sandrock

Moderator: Rudolph Tanzi, PhD, Vice-Chair of Neurology, Director of Ge...

  • Duration:
    24m 54s

Biogen's Alfred Sandrock Retires as Head of R...

Biogen's Alfred Sandrock Retires as Head of Resear...

On Nov15, 2021 Biogen announced that Dr. Alfred Sandrock Kr. M.D., Ph....

  • Duration:
    2m 37s

A Path Forward in Multiple Sclerosis (MS) Tre...

A Path Forward in Multiple Sclerosis (MS) Treatment

Alfred Sandrock, MD, PhD; Richard Rudick, MD; Richard Ransohoff, MD; a...

  • Duration:
    4m 29s

HOT TOPICS | Gene Expression | Modulating wit...

HOT TOPICS | Gene Expression | Modulating with Oli...

... R&D and CSO, Dicerna Pharmaceuticals Brett Monia, PhD, CEO, Ionis ...

  • Duration:
    25m 30s

2017 WNIF | Disease Modifying Therapies: Gett...

2017 WNIF | Disease Modifying Therapies: Getting O...

... PhD, SVP, Global Head of Neurosciences, GlaxoSmithKline Vivek Rama...

  • Duration:
    48m 56s

News

Biogen Gets Fda Approval For First Spinal Muscular Atrophy Treatment

Biogen gets FDA approval for first spinal muscular atrophy treatment

view source
  • This is exactly what we do at Biogen -- cutting-edge research and breakthrough therapies, said Alfred Sandrock, the companys chief medical officer. We feel a high sense of urgency to introduce it as soon as [it is] feasible to make sure patients get acccess to this drug.
  • Date: Dec 23, 2016
  • Category: Health
  • Source: Google
Fda Fast-Tracks Biogen Drug

FDA fast-tracks biogen drug

view source
  • By collaborating with regulators through programs like Fast Track, we hope to bring effective treatments to patients and families affected by Alzheimers disease as quickly as possible, said Dr. Alfred Sandrock, Biogens executive vice president and chief medical officer.
  • Date: Sep 03, 2016
  • Category: Health
  • Source: Google
Paper Alert: Aducanumab Phase 1B Study Published

Paper Alert: Aducanumab Phase 1b Study Published

view source
  • Incidences of brain-imaging abnormalities called ARIA-E, indicative of fluid build-up in the brain, also cropped up dose-dependently, but these abnormalities were transient. Alfred Sandrock of Biogen in Cambridge, Massachusetts, and Roger Nitsch of Neurimmune in Zurich co-led the trial. Some researc
  • Date: Sep 02, 2016
  • Category: Health
  • Source: Google
Early Research Shows 'Hint' Of Slowing Alzheimer's, But More Testing Is Needed

Early Research Shows 'Hint' Of Slowing Alzheimer's, But More Testing Is Needed

view source
  • Dr. Alfred Sandrock of Cambridge-based Biogen, and the study's senior author, summed up the researchhighlightsduring a press briefing in advance of the paper's release. He said the studyshowed that treatment with aducanumab, a human-derived monoclonal antibody, resulted in reducing the potentiall
  • Date: Aug 31, 2016
  • Category: Health
  • Source: Google
An Alzheimer's Drug Shows Serious Promise

An Alzheimer's Drug Shows Serious Promise

view source
  • We are pretty certain of the fact that the antibody reduces the amyloid plaques and in some ways gets rid of the majority of it, says Alfred Sandrock, senior author of the paper from Massachusetts-based Biogen. Thats important because if we really want to treat Alzheimers at even the very earli
  • Date: Aug 31, 2016
  • Category: Sci/Tech
  • Source: Google
Biogen (Biib), Ionis (Ions) Announce Nusinersen Phase 3 Met Primary Endpoint In Infantile-Onset Sma

Biogen (BIIB), Ionis (IONS) Announce Nusinersen Phase 3 Met Primary Endpoint in Infantile-Onset SMA

view source
  • rticipating in the clinical trials, who continue to inspire us. We want to thank them, along with the investigators who have worked tirelessly on this program and the broader SMA community, for their partnership. Without their contributions, we would not be here today, said Alfred Sandrock, M.D., Ph
  • Date: Aug 01, 2016
  • Category: Health
  • Source: Google
Biogen Shells Out $75M To Develop Ionis' Nusinersen After Positive Phase Iii Results

Biogen Shells Out $75M to Develop Ionis' Nusinersen after Positive Phase III Results

view source
  • We remain committed to understanding the potential of nusinersen in the broader SMA population and will continue to focus on the rapid completion of our ongoing studies, Alfred Sandrock, M.D., Ph.D., Biogen evp and CMO, said in a statement. We share the communitys sense of urgency as we strive t
  • Date: Aug 01, 2016
  • Category: Business
  • Source: Google
Biogen Tumbles On Phii Ms Flop, But Refuses To Write Off Drug

Biogen tumbles on PhII MS flop, but refuses to write off drug

view source
  • Despite these setbacks, Biogen has seen something in the data that could compel it to continue with development of the antibody. While we missed the primary endpoint, the SYNERGY study results suggest evidence of a clinical effect of opicinumab, Biogen CMO Alfred Sandrock said in a statement. Due
  • Date: Jun 07, 2016
  • Category: Business
  • Source: Google
Get Report for Alfred W Sandrock from Newbury Park, CADeceased
Control profile